skip to content

research · 544210 · healthcare

emcure.

the case for, the case against.

positivemedium convictionwritten 16 nov 2026, 17:16 ist · valid until 23 nov 2026

positive: the sourced evidence makes a specific case that the business is improving or under-appreciated. medium conviction: a reasonable case, resting on fewer or partly second-hand sources.

the case, in short
  • The international business grew 34.5% to INR1,665 crores and made up 59% of consolidated revenues, while India grew 12% to INR1,155 crores.

the main risk
  • Net debt stood at INR1,317 crores as of September, up INR263 crores from March '26.

in plain words

The international business grew 34.5% to INR1,665 crores and made up 59% of consolidated revenues, while India grew 12% to INR1,155 crores. The company raised its full-year FY27 revenue growth outlook and now expects revenue growth to exceed 20%, compared with the mid-teens it gave earlier. Net debt stood at INR1,317 crores as of September, up INR263 crores from March '26.

why it may work

  • The international business grew 34.5% to INR1,665 crores and made up 59% of consolidated revenues, while India grew 12% to INR1,155 crores.

  • The company raised its full-year FY27 revenue growth outlook and now expects revenue growth to exceed 20%, compared with the mid-teens it gave earlier.

what could go wrong

  • Net debt stood at INR1,317 crores as of September, up INR263 crores from March '26.

  • Finance cost was INR36 crores, reflecting higher borrowings that were taken to fund acquisition-related payouts.

  • Other income fell to INR16 crores from INR39 crores a year earlier, mainly because of lower foreign exchange gains.

price and valuation facts

  • Closed 0.7% below its 52-week closing high.
  • Last close ₹2,342.15 sits 98% of the way from the 52-week closing low (₹1,356.35) to the high (₹2,358.65).
  • Its largest fall from a peak in the last year was 12.9% (maximum drawdown).
  • P/E of 47.21x (standalone) is 28% below the median of its BSE 500 industry peers (sector peers when the industry has fewer than four).
  • Annualised volatility over 3 months is 34.8%, higher than 67% of the BSE 500 scrips Dalal tracks.
  • Median daily BSE traded value: ₹1.21 crore over 60 days.

dalal's own computed data (from exchange prices and bse fundamentals), not from the documents above. as of 16 nov 2026.

what is coming up

no dated events in the sources.

what would change the view

the view rests on these. if they stop being true, so does the view.

  • The company said it expects FY27 EBITDA margin improvement to be at the upper end of its 75 to 100 basis point guidance range.

  • The company said it remains committed to becoming net cash by the end of FY28.

the numbers

computed by dalal when the note was written.

price

last close
₹2,342.15
1-day change
−0.70%
52-week high (closing basis)
₹2,358.65
52-week low (closing basis)
₹1,356.35
52-week high (BSE, adjusted)
₹2,394.55
52-week low (BSE, adjusted)
₹1,325.00

as of 16 nov 2026

returns

1-week return
5.69%
1-month return
28.47%
3-month return
24.93%
6-month return
38.98%
12-month return
70.70%
3-month return relative to SENSEX
18.27%
6-month return relative to SENSEX
27.48%
12-month return relative to SENSEX
75.81%

as of 16 nov 2026

risk

annualised volatility (3 months)
34.78%
maximum drawdown (1 year)
−12.89%
distance from 52-week closing high
−0.70%
5-day vs 60-day BSE volume
5.00×

as of 16 nov 2026

valuation

P/E (standalone)
47.21×
P/E (consolidated)
40.66×
P/B
15.71×
EPS (standalone)
₹49.61
EPS (consolidated)
₹57.60
P/E relative to industry median
0.72×

as of 16 nov 2026

quality

return on equity
33.27%
operating margin
25.77%
net margin
14.89%

as of 16 nov 2026

size & liquidity

median daily BSE traded value (60 days)
₹1 cr
market capitalisation
₹44,433 cr

as of 16 nov 2026

latest results (standalone)

revenue, standalone (Sep-26)
₹1,668 cr
net profit, standalone (Sep-26)
₹248 cr
EPS, standalone (Sep-26)
₹13.10
operating margin, standalone (Sep-26)
25.77%
revenue, standalone (Jun-26)
₹1,451 cr
net profit, standalone (Jun-26)
₹200 cr
EPS, standalone (Jun-26)
₹10.55
operating margin, standalone (Jun-26)
25.13%
revenue change Jun-26 → Sep-26
14.96%
net profit change Jun-26 → Sep-26
24.15%

as of 14 nov 2026

dalal scores

daily score
100/100
monthly score
96/100
six-month score
99/100
long-term score
83/100

as of 16 nov 2026

not available: next results board meeting; days since last results filing.

· · . fundamentals from bse are standalone figures. scores are percentile ranks across the bse 500 (90 = better than 90% of them on that horizon’s recipe). 7 statements passed dalal’s source checks. 2 did not and are not shown.

pick history

every time it was listed, and how it went.

pick history with returns against the sensex
listlisted at1w1m3m
daily #2 · 17 nov 2026₹2,342.15 16 nov 2026–––

return minus the sensex over the same trading days, from the listed close.

in the knowledge base

the latest filings and news.

research ideas and things to consider, not personalised investment advice. every statement links to the filing or article it came from; numbers are computed by dalal from exchange data with their dates. ideas can and do lose money: the track record shows every pick, losers included. decide based on your own situation.